Understand the source comparison
Peptides for Back Pain: Comparison by Mechanism and Application
BPC-157 Activates FAK-paxillin pathway; upregulates VEGF receptor expression Tendons, ligaments, intervertebral discs Subcutaneous or intramuscular injection near injury site Increased tendon healing strength by 72% in rat Achilles injury models; reduced disc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Activates FAK-paxillin pathway; upregulates VEGF receptor expression
- Tendons, ligaments, intervertebral discs
- Subcutaneous or intramuscular injection near injury site
- Increased tendon healing strength by 72% in rat Achilles injury models; reduced disc inflammation markers in observational human studies
- Most evidence for structural repair in connective tissue. Limited but promising human data for chronic back pain
- TB-500 (Thymosin Beta-4)
- Promotes actin polymerization; enhances cell migration and angiogenesis
- Muscle tissue, ischemic regions, ligaments
- Subcutaneous injection (systemic effect)
- Increased angiogenesis markers by 58% in ischemic muscle; 23% improvement in rotator cuff surgery recovery
- Strong preclinical evidence for tissue regeneration. Extrapolation to spinal injury reasonable but unproven in controlled trials
- GHK-Cu (Copper Peptide)
- Chelates copper for lysyl oxidase activity; increases collagen cross-linking and reduces MMP-1
- Dermal and connective tissue, fibroblast-rich regions
- Topical, subcutaneous, or oral (bioavailability varies)
- 70% increase in collagen synthesis in human fibroblast cultures; reduced MMP-1 degradation in wound healing studies
- Well-validated for superficial tissue repair. Deep connective tissue application (e.g., spinal ligaments) is plausible but lacks direct clinical trials